CHT is a potent PKC inhibitor and antifungal compound that may have more significant therapeutic potential against candidiasis, especially in immunocompromised patients, due to its low toxicity and antitumor activity. The gene discussed is PRRT2; the disease is Candidiasis, Invasive.